Peptide News Digest

#FDA

126 stories

FDA coverage on Peptide News Digest follows the agency's actual paper trail: approval letters, warning letters, PCAC meeting minutes, 503A bulks list rulings, draft guidance, and Citizen Petitions on substances ranging from semaglutide to BPC-157.

The center of gravity in 2025 and 2026 has been compounding. Once GLP-1 shortages resolved, the agency turned to enforcement — 503A patient-specific compounding versus 503B outsourcing, which APIs sit on which list, what counts as a 'clinical need,' and whether additive formulations count as new drugs. The April 30, 2026 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list is the most consequential single move so far.

Outside GLP-1, the FDA has been active on peptide-vendor warning letters, advisory committee votes (PCAC, Endocrinologic and Metabolic Drugs), and the long grind of Section 503A's bulks list. Browse the latest below.

Regulatory · View digest

FDA Requires a Warning About NAION, a Rare Cause of Sudden Vision Loss, on Every GLP-1 Drug

The FDA said on November 9 that it is requiring all GLP-1 receptor agonists, including Ozempic, Wegovy, Mounjaro, Zepbound, and Foundayo, to add nonarteritic anterior ischemic optic neuropathy (NAION) to the Warnings and Precautions section of their labels, concluding there is a "potential increased risk of rare NAION events." In a pooled analysis of 126 randomized trials with 134,253 patients, probable NAION occurred at 6.4 events per 100,000 person-years on GLP-1 drugs vs. 3.8 on placebo or other glucose-lowering drugs (10 events vs. 5, all 5 on placebo), and an FDA Sentinel study in type 2 diabetes found a hazard ratio of 1.43 vs. DPP-4 inhibitors (95% CI 1.02 to 2.01) but no significant difference vs. SGLT2 inhibitors. The agency tells patients to seek care right away for sudden, painless vision loss in one eye and tells clinicians to consider stopping the drug in patients who develop NAION.

Regulatory · View digest

AP: HHS Dropped a Plan to Declare Six Peptides Safe for Compounding After FDA Scientists Refused to Back It

Citing six people familiar with the policy, the Associated Press reported that HHS first wanted the FDA to write a rule adding BPC-157 and other peptides to the list of substances safe for compounding, then switched to a promise not to enforce after agency scientists would not support it. FDA staff did get some safeguards added: ingredients from FDA-registered factories, side-effect reporting, and purity checks. Former FDA official Peter Lurie said the agency lacks the legal authority to enforce those pharmacy requirements.

Regulatory · View digest

FDA Enforcement Report Lists Sterility Recalls of Compounded Tirzepatide, Semaglutide, B12 Blends, and Sermorelin From Two Carolina Compounders

FDA's October 14, 2026 enforcement report lists 18 Class II recall entries, classified October 8, for compounded injectables for lack of assurance of sterility. Apothecary Pharma of Cary, North Carolina recalled 22 multi-dose vials of tirzepatide 18 mg/mL and one NAD+ vial distributed nationwide, starting September 24; Carolina Infusion of Ridgeland, South Carolina recalled patient-specific syringes of tirzepatide, tirzepatide and semaglutide blended with cyanocobalamin (vitamin B12), semaglutide, sermorelin, and erectile-dysfunction mixes, citing processing equipment and, for some products, a formulation using bacteriostatic water. Fox station coverage on October 21 noted that no illnesses or injuries were reported and that FDA had sent Apothecary Pharma a warning letter in December 2025 over sterile manufacturing practices, without linking it to the recall.

Regulatory · View digest

FDA Inspectors Found Black Mold, Insects, and Discarded Samples at a Chinese Plant Making Semaglutide and Tirzepatide Ingredients for Compounding

FDA inspection reports obtained by Bloomberg through a Freedom of Information Act request describe black mold on equipment, "gross contamination" on floors, and "significant insect activity" in ceilings at Chengdu Shengnuo Biopharm in southwest China, inspected in August, where staff moved documents to lockers and poured product samples into sinks. A September inspection found that Nanjing Chengong Pharmaceutical had bought active ingredients from other factories and applied its own seal without reviewing their test data. FDA's Import Alert 66-40 lists Chengdu Shengnuo as of September 19, 2026 and Nanjing Chengong as of October 1, so their products can be detained at the U.S. border; the companies made semaglutide and tirzepatide ingredients used in compounded drugs.

Regulatory · View digest

Sen. Jim Banks Leads Senators Urging FDA to Close the 'Research Use Only' Loophole Used to Sell Retatrutide, Citing a 265% Rise in Poisonings

Sen. Jim Banks (R-Ind.) led a group of senators in an October 14, 2026 letter, released October 15, to Acting FDA Commissioner Diamantas asking the agency to work more closely with U.S. Customs and Border Protection against vendors that sell unapproved drugs, including knockoff retatrutide, labeled "for research use only." The letter cites America's Poison Centers data showing a 265% increase in poisonings related to illicit retatrutide in the first four months of 2026 compared with the last four months of 2025, and asks for an FDA briefing on enforcement; STAT reported on October 20 that the push is bipartisan.

Regulatory · View digest

HHS and FDA Send an 'Interim Access Policy for Compounding Using Certain Peptides' to the White House for Review

HHS and the FDA submitted an "interim access policy for compounding using certain peptides" to the White House Office of Management and Budget for review, according to a government filing reported by Reuters and the Associated Press on October 15, 2026. The filing gives no details, but AP, citing two people familiar with the plan, reported that it would let specialty compounding pharmacies temporarily make some popular peptides, including BPC-157, through enforcement discretion, meaning the FDA would choose not to act against them. Formally adding the peptides to the FDA's compounding list would still require rulemaking, and FDA staff scientists said in July that none had been studied enough to establish safety and effectiveness.

Regulatory · View digest

Washington Post: Administration Drafting a Plan to Let Some Restricted Peptides Be Sold Temporarily Through Compounding Pharmacies

The Washington Post reported on October 7, 2026, citing two people familiar with the matter, that the Trump administration is drafting plans to allow temporary sales of some previously restricted peptides while federal health officials write new rules for them; Reuters carried the report, and a summary of the article says the plan would cover seven peptides sold through compounding pharmacies. The plan had not been announced and could change. It follows the FDA advisory committee's July 2026 votes on peptides such as BPC-157; before those votes, FDA career scientists had said the evidence was too weak to support compounding them.

Regulatory · View digest

FDA Extends Review of Novo Nordisk's Hemophilia A Drug Denecimig Over Manufacturing-Site Fixes; U.S. Launch Now Aimed for First Half of 2027

Novo Nordisk said on Friday, October 2, 2026 that the FDA's review of its biologics license application for denecimig, a bispecific antibody that mimics activated clotting factor VIII in hemophilia A, is still ongoing with no new action date because of remediation work at a manufacturing facility. Novo filed in September 2025 and had expected a decision in the third quarter of 2026; the FDA has not identified deficiencies in the clinical efficacy or safety data, and Novo now aims to launch in the U.S. in the first half of 2027. The company said the delay does not change its 2026 financial outlook.

Regulatory · View digest

Stem Cell Advocates at the PepMed 2026 Peptide Conference Seek the FDA Openness That Compounded Peptides Have Gained

STAT reported on Monday, October 5, 2026 from PepMed 2026, a conference for regenerative health businesses held by the American Academy of Peptide Medicine, that stem cell entrepreneurs see the FDA's recent openness to compounded peptides as a model for bringing unapproved stem cell therapies out of the gray market. Entrepreneur Chuck Meeker predicted a series of FDA roundtables on stem cells before the end of the year; the FDA declined to say whether any were planned. Commercially sold, unapproved stem cell therapies have remained out of favor with the agency.

Regulatory · View digest

FDA Peptide Compounding Regulatory Status Continues Unchanged 46 Days After July PCAC Vote; No Proposed Rule, No Federal Register Notice

As of Tuesday September 8, 2026, the FDA has issued no proposed rule, no Federal Register notice, and no interim enforcement policy following the July 23-24, 2026 Pharmacy Compounding Advisory Committee (PCAC) 5-3 vote recommending six of seven candidate peptides — BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon — for inclusion on the Section 503A Bulk Drug Substances List; emideltide (DSIP) was rejected. Forty-six days have passed since the meeting ended on July 24. Center for Drug Evaluation and Research warning-letter activity to compounding pharmacies has remained elevated through Q3 2026, and no acting-FDA-commissioner statement has updated the industry timeline. The February 2027 PCAC meeting to consider cathelicidin (LL-37), GHK-Cu, dihexa acetate, melanotan II, and PEG-MGF remains scheduled. Nominated FDA Commissioner Dr. Heidi Overton (August 19, 2026) continues to await Senate confirmation with Kyle Diamantas leading the agency in the interim. Formal FDA rulemaking to translate the PCAC recommendation into a proposed rule and then a final rule typically runs 12 to 24 months from PCAC vote; the interval of 46 days is within the normal window but longer than industry advocates had modeled at the meeting.

Regulatory · View digest

FDA Peptide Compounding Regulatory Limbo Continues 44 Days After July 24 PCAC Meeting; Still No Proposed Rule, No Federal Register Notice

As of Sunday September 6, 2026, the FDA has issued no proposed rule, no Federal Register notice, and no interim enforcement policy following the July 23-24, 2026 Pharmacy Compounding Advisory Committee (PCAC) vote to recommend six peptides — BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon — for inclusion on the Section 503A Bulk Drug Substances List. The regulatory silence has now lasted 44 days since the meeting ended on July 24, and compounding pharmacies continue to operate in the gray zone that began with the April 22, 2026 removal of 12 peptides from Category 2. Center for Drug Evaluation and Research warning-letter activity to compounding pharmacies remained elevated through Q3 2026. The February 2027 PCAC meeting to consider cathelicidin (LL-37), GHK-Cu, dihexa acetate, melanotan II, and pegylated mechano growth factor (PEG-MGF) remains scheduled. Dr. Heidi Overton (nominated FDA Commissioner August 19, 2026) continues to await Senate confirmation. Formal FDA rulemaking to translate the July PCAC recommendation into a proposed rule and then a final rule typically runs 12 to 24 months from PCAC vote; the interval of just over six weeks is within the normal window but longer than industry advocates had modeled.

Regulatory · View digest

FDA Peptide Compounding Regulatory Limbo Enters Seventh Week Since July 23-24 PCAC Vote; No Proposed Rule, No Interim Enforcement Policy

As of Saturday September 5, 2026, the FDA has issued no proposed rule, no Federal Register notice, and no interim enforcement policy following the July 23-24, 2026 Pharmacy Compounding Advisory Committee (PCAC) vote to recommend six peptides — BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon — for inclusion on the Section 503A Bulk Drug Substances List. The regulatory silence has now extended six weeks past the vote and continues to leave compounding pharmacies operating in the gray zone that began with the April 22, 2026 removal of 12 peptides from Category 2. Center for Drug Evaluation and Research warning-letter activity to compounding pharmacies has remained elevated through Q3 2026. The February 2027 PCAC meeting to consider cathelicidin (LL-37), GHK-Cu, dihexa acetate, melanotan II, and pegylated mechano growth factor (PEG-MGF) remains scheduled. Dr. Heidi Overton (nominated FDA Commissioner August 19, 2026) continues to await Senate confirmation with acting Commissioner Kyle Diamantas leading the agency through the interim.

Regulatory · View digest

FDA Announces September 25 Joint Workshop With European Medicines Agency on Botanical Drug Product Development Regulations

The U.S. Food and Drug Administration confirmed via press announcement Friday September 4, 2026 that it will convene a joint workshop with the European Medicines Agency (EMA) on Friday September 25, 2026 to discuss regulatory considerations for herbal medicinal and botanical drug products intended for medicinal use. The workshop follows the FDA's ongoing public-input process on botanical drug development that generated substantial biotech and pharmaceutical industry commentary earlier in 2026. Botanical drugs occupy an underdeveloped regulatory category in the U.S. — FDA has approved only two botanical drugs to date (Veregen sinecatechins from green tea for genital warts, approved 2006; Fulyzaq crofelemer from Croton lechleri sap for HIV-related diarrhea, approved 2012). Proposed legislation in the U.S. would extend 12-year market exclusivity to FDA-approved botanical drugs, matching the biologics exclusivity framework. The Sept 25 workshop matters for the peptide-industry pipeline because plant-derived and marine-organism-derived peptide products (defensins, ranatuerin analogs, plant-defensin-based antimicrobials) occupy a similar regulatory gray zone between conventional pharmaceuticals and dietary supplements.

Regulatory · View digest

FDA Peptide Compounding Regulatory Limbo Enters Month Six Since July 23-24 PCAC Vote; No Proposed Rule, No Federal Register Notice, No Interim Enforcement Policy

As of Thursday September 3, 2026, the FDA has issued no proposed rule, no Federal Register notice, and no interim enforcement policy following the July 23-24, 2026 Pharmacy Compounding Advisory Committee (PCAC) vote to recommend six peptides — BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon — for inclusion on the Section 503A Bulk Drug Substances List. The regulatory silence extends the gray zone that began with the April 22, 2026 removal of 12 peptides from Category 2 and continues to leave compounding pharmacies operating under enforcement risk. CDER warning-letter activity to compounding pharmacies remained elevated through Q3 2026 versus prior years. The February 2027 PCAC meeting to consider cathelicidin (LL-37), GHK-Cu, dihexa acetate, melanotan II, and pegylated mechano growth factor (PEG-MGF) remains scheduled; formal FDA rulemaking to translate PCAC recommendations into a proposed rule typically runs 6 to 18 months. The FDA Commissioner nomination of Dr. Heidi Overton continues to await Senate confirmation, with acting Commissioner Kyle Diamantas leading the agency through the interim.

Regulatory · View digest

Holland & Knight and Mondaq Legal Analyses Published Following the July 23-24 FDA Pharmacy Compounding Advisory Committee (PCAC) Vote Clarify the Rulemaking Process for the Six Recommended Peptides (BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon): HHS Secretary Robert F. Kennedy Jr. Must Formally Approve the Substances for 503A Bulks List Inclusion, and No Compounding Is Permitted Until Final Rulemaking Completes (Typically 12-24 Months From Advisory-Committee Recommendation); The FDA Has Announced a Second PCAC Peptide Meeting Before the End of February 2027 to Review Five Additional Peptides (Cathelicidin/LL-37, GHK-Cu, Dihexa Acetate, Melanotan II, PEG-MGF)

Holland & Knight and Mondaq legal analyses published following the July 23-24, 2026 FDA Pharmacy Compounding Advisory Committee (PCAC) vote clarify the rulemaking process for the six recommended peptides (BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon; Emideltide/DSIP rejected). Key legal clarifications: PCAC recommendations are advisory only; HHS Secretary Robert F. Kennedy Jr. must formally approve the substances for Section 503A Bulks List inclusion; no compounding pharmacy is permitted to legally compound the peptides until final rulemaking completes; formal rulemaking typically takes 12-24 months from advisory-committee recommendation (Notice of Proposed Rulemaking, public comment period, response to comments, final rule with effective date). Even after final rule takes effect, individual states retain authority under state pharmacy board oversight to further restrict or condition compounded-peptide preparation. Separately, the FDA has announced a second PCAC peptide meeting before the end of February 2027 to review five additional peptides: cathelicidin (LL-37, antimicrobial peptide), GHK-Cu (copper tripeptide cosmetic peptide), dihexa acetate (nootropic), melanotan II (α-MSH analog), and pegylated mechano growth factor (PEG-MGF, muscle repair). Combined, the July 2026 and February 2027 PCAC dockets bring 12 peptides through advisory-committee review as part of the broader Trump administration and HHS Secretary RFK Jr. peptide deregulation agenda that has moved through the regulatory system since Q1 2026.

Regulatory · View digest

FDA Pharmacy Compounding Advisory Committee (PCAC) Has Scheduled a Second Peptide Meeting Before the End of February 2027 to Review Five Additional Peptides for Section 503A Bulks List Inclusion Following the July 23-24, 2026 Session That Recommended 6 of 7 Peptides (BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon; DSIP Rejected); The February 2027 Docket Covers Cathelicidin (LL-37, Antimicrobial Peptide With Broad Anti-Infective and Immune-Modulatory Activity), GHK-Cu (Copper Tripeptide Widely Marketed in Cosmetic and Wound-Healing Formulations), Dihexa Acetate (Angiotensin-Derived Nootropic), Melanotan II (α-MSH Analog for Skin Pigmentation and Appetite Suppression), and Pegylated Mechano Growth Factor (PEG-MGF, Muscle Repair Peptide)

The FDA Pharmacy Compounding Advisory Committee (PCAC) has scheduled a second peptide meeting before the end of February 2027 to review five additional peptides for Section 503A Bulks List inclusion. The February 2027 docket covers: cathelicidin (LL-37), a broad-spectrum antimicrobial peptide with anti-infective and immune-modulatory activity; GHK-Cu (glycyl-histidyl-lysine copper tripeptide), a widely-marketed cosmetic and wound-healing peptide previously in FDA Category 2; dihexa acetate, an angiotensin IV-derived nootropic that has been marketed for cognitive enhancement; melanotan II, an alpha-melanocyte-stimulating hormone analog marketed for skin pigmentation (self-tanning) and appetite suppression; and pegylated mechano growth factor (PEG-MGF), a muscle-repair peptide derived from insulin-like growth factor 1 splice variants. The February 2027 review continues the July 23-24, 2026 PCAC session that recommended 6 of 7 peptides for Section 503A Bulks List inclusion (BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon approved; Emideltide/DSIP rejected). FDA has not yet posted the final date and public-comment docket details for the February 2027 meeting. Under standard rulemaking timelines, the FDA's process of Notice of Proposed Rulemaking, public comment period, and final rule after any positive PCAC recommendation takes 12-24 months.

Regulatory · View digest

FDA Public Comment Period on the April 30, 2026 Proposed Rule to Permanently Exclude Semaglutide, Tirzepatide, and Liraglutide From the Section 503B Bulks List Closed Thursday July 30, 2026 After a Federal Register-Extended Deadline From the Original June 29 Cutoff; The FDA Found No Clinical Need for Outsourcing Facilities to Compound the Three GLP-1 Molecules From Bulk Drug Substances; Finalization of the Rule Would Close the Last Legal Pathway for Large-Scale FDA-Registered 503B Outsourcing Facility Compounding of the Branded GLP-1s, Following the December 2024 Semaglutide Shortage Resolution and February 2025 Tirzepatide Shortage Resolution

The FDA public comment period on the April 30, 2026 proposed rule to permanently exclude semaglutide, tirzepatide, and liraglutide from the Section 503B Bulks List closed Thursday July 30, 2026 after a Federal Register-extended deadline from the original June 29 cutoff. The FDA's underlying finding: no clinical need for FDA-registered outsourcing facilities to compound the three GLP-1 molecules from bulk drug substances. Section 503B outsourcing facilities are the FDA-registered large-scale compounding manufacturers (as distinct from state-licensed 503A pharmacies that compound for individual patient prescriptions). Finalization of the proposed rule would close the last legal pathway for large-scale FDA-registered 503B outsourcing facility compounding of the branded GLP-1 molecules, following the December 2024 semaglutide shortage resolution and February 2025 tirzepatide shortage resolution that ended the shortage-based compounding pathway. FDA rulemaking to finalize the exclusion after comment-period close typically takes 3-9 months depending on the volume and substance of received comments. Telehealth platforms including Hims & Hers Health (NYSE: HIMS) and LifeMD have already migrated to branded supply through Novo Nordisk and Eli Lilly commercial channels ahead of the expected 503B closure. FDA Adverse Event Reporting System (FAERS) data as of the July 2026 safety statement: 990 adverse events linked to compounded semaglutide, over 730 for compounded tirzepatide.

Regulatory · View digest

FDA Public Comment Period Closes Thursday July 30, 2026 on the April 30, 2026 Proposed Rule to Permanently Exclude Semaglutide, Tirzepatide, and Liraglutide From the Section 503B Bulks List, Which Would Close the Last Legal Pathway for Large-Scale FDA-Registered Outsourcing Facility Compounding of the Branded GLP-1 Molecules; Docket Followed the FDA Category-2-Unwind Timeline That Also Culminated in the July 23-24 Pharmacy Compounding Advisory Committee (PCAC) Vote Recommending 6 of 7 Peptides for Section 503A Bulks List Inclusion

The FDA public comment period on the April 30, 2026 proposed rule to permanently exclude semaglutide, tirzepatide, and liraglutide from the Section 503B Bulks List closed Thursday July 30, 2026. If the FDA finalizes the rule, large-scale FDA-registered 503B outsourcing facilities will no longer be able to legally prepare compounded semaglutide, tirzepatide, or liraglutide once the shortage-based compounding pathway has fully closed. The 503B exclusion is the parallel-track regulatory action to the July 23-24 PCAC vote on the 7 research peptides for the 503A Bulks List. Where 503A operates under state pharmacy board licensure for individual-patient prescriptions, 503B operates under FDA registration for bulk manufacturing at outsourcing facilities. The 503A vote broadened access to 6 of 7 research peptides (BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon; DSIP rejected). The 503B exclusion narrows access for the branded GLP-1 franchise. Both actions require FDA rulemaking to formalize, with typical timelines of 6-18 months from the date the agency decides to act. Telehealth companies including Hims & Hers Health (NYSE: HIMS) and LifeMD (NASDAQ: LFMD) have already migrated to branded supply through Novo Nordisk and Eli Lilly commercial channels ahead of the expected 503B closure.